Forxiga generics, Jardiance·Envlo, surpass original drug

in sales

'Set to withdraw from KOR' Forxiga's Q2 prescription sales totaled KRW 10.4 billion…sales of 65 generics totaled KRW 10.6 billion

Envlo, a new drug in KOR, had a sixfold increase in sales over a year …Jardiance is the top-selling drug in the market for SGLT2i monotherapy

Generic versions of metformin combination therapy dominate in the market…sales of Jardiance Duo 'stalled'·Xigduo 'decreased'

(Clockwise from upper left) Product photos of AstraZeneca

The market for SGLT-2 inhibitors used to treat diabetes is shifting due to advancing generics and new drugs made in South Korea.

 

The prescription sales of Forxiga (dapagliflozin), which is set to withdraw from South Korea, have significantly dropped.

 

In contrast, the prescription sales of Forxiga generics quickly increased, surpassing those of the original drug in one year since its launch.

 

Similarly, the prescription sales of the new drug in South Korea, 'Envlo (enavogliflozin),' have expanded over sixfold over a year.

 

Analysis suggests that when Forxiga withdraws from the market in the second half of the year, Envlo will likely take second place in the market.

 

'Set to withdraw from KOR,' Forxiga's prescription sales↓by 26%...generics surpass the original drug According to the medicinal market research firm UBIST on July 17th, Forxiga's out-patient prescription sales in Q2 totaled KRW 10.4 billion, a 26% decrease in a year compared to KRW 14.1 billion in Q2 of last year.

 

Analysis suggests that emerging generics after the patent expiration and the decision to withdraw from the Korean market may have affected Forxiga's prescription sales reduction.

 

The Forxiga patent expired in April of last year.

 

Since then, 65 generics have been launched.

 

In December, AstraZeneca Korea has decided to withdraw Forxiga from the Korean market.

 

The company plans to withdraw Forxiga, a monotherapy drug, and only leave 'Xigduo,' a combination therapy drug containing metformin.

 

Currently, AstraZeneca Korea only provides the existing stock without additional imports from the global headquarters.

 

While the Forxiga sales stalled, generics containing the same ingredient have expanded their market influences.

 

In particular, the Q2 prescription sales of generics surpassed that of the original drug for the first time.

 

In Q2, the prescription sales of 65 Forxiga generics totaled KRW 10.6 billion, a threefold increase from KRW 3.9 billion in Q2 last year.

 

As Forxiga's sales declined in prescription sales, generics sales skyrocketed, resulting in generics turning around.

 

Quarterly prescription sales of the original Forxiga and its generic version (unit: KRW 100 million, source: UBIST).

Among the generics, Boryung's 'Trudapa' has recorded the highest prescription performance in Q2, with KRW 1.1 billion, followed by Hanmi Pharm's 'Dapalon (KRW 900 million),' Aju Pharm's 'Dapril (KRW 800 million),' Chong Kun Dang's 'Exiglu (KRW 600 million),' and Kyung Dong Pharma's 'Dapazin'·DongA ST's 'Dapapro'·Daewon Pharmaceutical's 'Dapaone' (KRW 500 million, respectively).

 

The pharmaceutical industry anticipates that the prescription sales of generics will increase more rapidly in the second half of the year.

 

Once the remaining stock of Forxiga starts to deplete, generics are likely to quickly dominate the market.

 

On this note, the industry eyes on HK inno.N’s generic ‘Dapa N.’ Dapa N succeeded Forxiga's heart failure and kidney disease indications.

 

In April, AstraZeneca announced that they would withdraw the BLA of Forxiga and transfer Forxiga's heart failure and kidney disease indications by granting clinical documents.

 

As a result, Dapa N became the only generic product that gained the indication of the original drug.

 

The industry expects the drug to start experiencing indication advantage in the second half of the year.

 

The sales of Envlo, a new drug in South Korea, have increased 5.6 fold over a year…Jardiance has been the market leader for a year The prescription sales of Boehringer Ingelheim's Jardiance (empagliflozin) and Daewoong Pharmaceutical's Envlo have increased.

 

It seems that the expected withdrawal of Forxiga from the Korean market may have partially influenced this trend.

 

Jardiance has been the market leader since Q2 last year when the Forxiga patent expired.

 

Since then, its prescription sales have been continuously increased.

 

Jardiance's prescription sales for this Q2 totaled KRW 16.1 billion, up 10% YoY from KRW 14.6 billion.

 

The 36th new drug in Korea, Envlo, is also quickly expanding prescription sales after its launch in May last year.

 

The Q2 prescription sales of Envlo amounted to KRW 2.5 billion, an increase of 5.8-fold compared to KRW 400 million YoY.

 

Summing together with HanAll Biopharma’s 'Eaglex' and Daewoong Pharmaceutical's 'Benavo,' both of which were launched at the time of Envlo, the prescription sales of these generics increased from KRW 500 million to KRW 2.8 billion over a year, an increase by 5.6-fold.

 

Prescription sales of SGLT-2 inhibitors used to treat diabetes: Forxiga, Forxiga generics, Jardiance, Envlo, Suglat, and Steglatro (unit: KRW 100 million, source: UBIST).

The industry expects Envlo's sales to continue increasing after this year.

 

It seems that Envlo is expected to become the no.2 in the market for SGLT-2 inhibitor monotherapy, surpassing Forxiga within this year as the prescription sales of Forxiga are expected to decline quickly.

 

Meanwhile, the sales of Astellas Pharma's 'Suglat (ipragliflozin)' and MSD's 'Steglatro (ertugliflozin)' continued to stall for a long time.

 

Over a year, the prescription sales of Suglat declined from KRW 1 billion to KRW 900 million, and that of Steglatro declined from KRW 300 million to KRW 100 million.

 

These companies have decided to withdraw from the market due to low sales.

 

Generics' sales are increasing in the market for combination therapies…over a year, KRW 2.1 billion→KRW 6.4 billion The sales of generics are increasing in the market for combination therapies containing SGLT-2 inhibitor and metformin.

 

In Q2, the prescription sales of 35 products that are generic versions of Xigduo (dapagliflozin+metformin) totaled KRW 6.4 billion.

 

This figure marked an over threefold increase from KRW 2.1 billion in Q2 last year.

 

Boryung's 'Trudapa M' and Hanmi Pharm's 'Dapalon Duo' recorded KRW 1.1 billion, followed by Aju Pharms' 'Dapril Duo'·Kyung Dong Pharma's 'Dapamet' (KRW 800 million, respectively), and Daewon Pharmaceutical's 'Dapawon-M' (KRW 500 million).

 

However, 20 other companies manufacturing generics recorded the prescription sales below KRW 100 million in Q2.

 

AstraZeneca's Xigduo remains the no.1 in the market for combination therapies, with KRW 10.4 billion in prescription sales.

 

However, sales were reduced by 15% from KRW 12.2 billion in Q2 last year.

 

The industry anticipates a significant reduction in Xigduo's prescription sales in the second half of this year due to a price reduction next month.

 

The price reduction was delayed at AstraZeneca's request for execution suspension.

 

The prescription sales of Boehringer Ingelheim's 'Jardiance Duo (empagliflozin+metformin)' saw a 4% increase from KRW 9.9 billion in Q2 last year to KRW 10.2 billion.

 

'Envlomet (enavogliflozin+metformin)' recorded KRW 400 million in prescription sales in Q2 this year.

 

Daewoong Pharmaceutical launched Envlomet in November last year.